Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsInitiationPrice Target
Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.